New Device Shows Promise in Treating Chronic Migraine

Breakthrough Neurostimulation System Unveiled

ShiraTronics has shared promising data from its RELIEV-CM Pilot Study, introducing a pioneering neurostimulation system for chronic migraine. The findings were presented at the ASPN Pain Conference, drawing attention to a potentially transformative treatment for those suffering from persistent migraines.

Dr. Steven Falowski, a leading neurosurgeon, reported on the 12-week results. He highlighted ShiraTronics’ new device, which offers continuous, minimally invasive stimulation specifically designed for the head, aiming to reduce migraine frequency and improve patients' quality of life.

Details of the RELIEV-CM Pilot Study

The RELIEV-CM Pilot Study investigates the ShiraTronics Migraine Therapy System’s early safety and effectiveness. This system caters to chronic migraine sufferers, characterized by severe headaches occurring at least 15 days a month, often with debilitating symptoms like nausea and light sensitivity.

Unlike traditional systems typically placed along the spine, ShiraTronics' device utilizes precise electrical pulses aimed at the occipital and supraorbital nerves. This innovative approach aims to provide continuous relief uniquely suited for individuals with chronic migraines.

Key Data from the Study

Dr. Falowski revealed significant reductions in migraine frequency and improvements in quality-of-life measures among study participants. For many chronic migraine patients, this device may herald a new era in pain management.

This novel system aims to address the limitations of current treatments, providing consistent and lasting relief through a fully implantable, head-located device. Such innovations could potentially improve the lives of millions of chronic migraine sufferers globally.

Expert Insights and Future Directions

Dr. Matthew Green, involved in the initial implants in Australia, emphasized the positive impacts observed during the pilot study. He noted substantial improvements in participants' pain levels and the number of migraine days, encouraging further exploration in subsequent trials.

The upcoming randomized controlled trials will be crucial in confirming these positive outcomes and determining the device's long-term benefits. These trials aim to expand our understanding of how such technological advancements can effectively treat chronic migraines.

ShiraTronics' Commitment to Innovation

ShiraTronics is dedicated to enhancing quality of life through state-of-the-art neurostimulation solutions. Rob Binney, President and CEO, expressed enthusiasm about the pilot study's results, reinforcing the company's dedication to addressing chronic migraine sufferers' needs.

The promising preliminary data indicate that ShiraTronics' innovative platform could significantly improve patient outcomes. The company plans to accelerate further clinical research, continuing its mission to offer effective, life-changing therapies for chronic migraine sufferers.

For further information on ShiraTronics and the RELIEV-CM study, visit their [website](https://www.shiratronics.com).